GlaxoSmithKline Intellectual Property Development
Part of GSK
Company
GlaxoSmithKline Intellectual Property Development develops 2 assets, the furthest in phase 3, no development reported (sotrovimab in COVID-19). Mostly antibody acting on S.
- 2
- Assets
- Furthest stage
- Phase 3, no development reported
- 0
- Trials
- 0
- Signals
Pipeline
2Monoclonal antibody engineered for immune engagement.
Phase 3, no development reported, Antibody, S, COVID-19, Partner
Binds SARS-CoV-2 spike protein to neutralize the virus, with an engineered Fc region enhancing immune effector functions.
Preclinical, no development reported, Antibody, COVID-19, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Signals4
- Similar companies6